Selected Publications
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era Blood Adv 9 : 533-544,2025.
Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation Transplantation and Cellular Therapy : 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen Eur J Haematol : 2025.
Pratz KW, Erba HP.: Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents Am J Hematol : 2025.
Pratz KW.: Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1 Br J Haematol : 2024.
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C: The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia Am J Hematol : 2024.
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Haematologica 109 (8): 2732-2737,2024.
12., Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D: Ven the dose matters: Venetoclax dosing in the frontline treatment of AML Blood Rev : 2024.
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA: Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine Blood : 2024.
Hamilton KW, Hua E, Dutcher L, Fernandez Lynch H, Junker P, Doucette AG, Werner D, Kannel EZ, Civitello T, Gabriel P, Ahya VN, Jacobs DA, Garfall A, Pratz K, Degnan KO, Blumberg EA, Capozzi D, Craig E, Takach P, Payne AS, Geara A, Koenig H, Holzman L, Tebas P: Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center Open Forum Infect Dis. 11 (8): 2024.
Academic Contact Information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia,
PA
19104
Patient appointments: 800-789-7366